Literature DB >> 19498432

Neurodegenerative disease: Diabetes, microvascular pathology and Alzheimer disease.

Raj N Kalaria1.   

Abstract

Epidemiological studies suggest that the risk of developing cognitive impairment and dementia is increased in individuals with diabetes mellitus, although the evidence from clinicopathological studies on neurodegenerative changes is at odds with these observations. A thorough appraisal of concomitant vascular changes in dementia might resolve this incongruity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19498432     DOI: 10.1038/nrneurol.2009.72

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


  10 in total

Review 1.  Brain imaging in patients with diabetes: a systematic review.

Authors:  Barbera van Harten; Frank-Erik de Leeuw; Henry C Weinstein; Philip Scheltens; Geert Jan Biessels
Journal:  Diabetes Care       Date:  2006-11       Impact factor: 19.112

2.  Beta-amyloid deposition in brains of subjects with diabetes.

Authors:  I Alafuzoff; L Aho; S Helisalmi; A Mannermaa; H Soininen
Journal:  Neuropathol Appl Neurobiol       Date:  2008-03-10       Impact factor: 8.090

Review 3.  Human cerebral neuropathology of Type 2 diabetes mellitus.

Authors:  Peter T Nelson; Charles D Smith; Erin A Abner; Frederick A Schmitt; Stephen W Scheff; Gregory J Davis; Jeffrey N Keller; Gregory A Jicha; Daron Davis; Wang Wang-Xia; Adria Hartman; Douglas G Katz; William R Markesbery
Journal:  Biochim Biophys Acta       Date:  2008-08-22

4.  Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study.

Authors:  Rita Peila; Beatriz L Rodriguez; Lenore J Launer
Journal:  Diabetes       Date:  2002-04       Impact factor: 9.461

Review 5.  Towards defining the neuropathological substrates of vascular dementia.

Authors:  Raj N Kalaria; Rose Anne Kenny; Clive G Ballard; Robert Perry; Paul Ince; Tuomo Polvikoski
Journal:  J Neurol Sci       Date:  2004-11-15       Impact factor: 3.181

6.  Diabetes is related to cerebral infarction but not to AD pathology in older persons.

Authors:  Z Arvanitakis; J A Schneider; R S Wilson; Y Li; S E Arnold; Z Wang; D A Bennett
Journal:  Neurology       Date:  2006-12-12       Impact factor: 9.910

7.  Uncontrolled diabetes increases the risk of Alzheimer's disease: a population-based cohort study.

Authors:  W L Xu; E von Strauss; C X Qiu; B Winblad; L Fratiglioni
Journal:  Diabetologia       Date:  2009-03-12       Impact factor: 10.122

8.  Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology.

Authors:  M S Beeri; J Schmeidler; J M Silverman; S Gandy; M Wysocki; C M Hannigan; D P Purohit; G Lesser; H T Grossman; V Haroutunian
Journal:  Neurology       Date:  2008-09-02       Impact factor: 9.910

Review 9.  Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials.

Authors:  Donna M Wilcock; Carol A Colton
Journal:  J Alzheimers Dis       Date:  2008-12       Impact factor: 4.472

10.  Different patterns of cerebral injury in dementia with or without diabetes.

Authors:  Joshua A Sonnen; Eric B Larson; Kiri Brickell; Paul K Crane; Randall Woltjer; Thomas J Montine; Suzanne Craft
Journal:  Arch Neurol       Date:  2009-01-12
  10 in total
  36 in total

Review 1.  The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia.

Authors:  Costantino Iadecola
Journal:  Acta Neuropathol       Date:  2010-07-11       Impact factor: 17.088

Review 2.  Type 2 diabetes and cognitive compromise: potential roles of diabetes-related therapies.

Authors:  Efrat Kravitz; James Schmeidler; Michal Schnaider Beeri
Journal:  Endocrinol Metab Clin North Am       Date:  2013-09       Impact factor: 4.741

Review 3.  New views and possibilities of antidiabetic drugs in treating and/or preventing mild cognitive impairment and Alzheimer's Disease.

Authors:  Kai Long Zhong; Fang Chen; Hao Hong; Xuan Ke; Yang Ge Lv; Su Su Tang; Yu Bing Zhu
Journal:  Metab Brain Dis       Date:  2018-04-06       Impact factor: 3.584

4.  Design, Synthesis, and X-ray of Selenides as New Class of Agents for Prevention of Diabetic Cerebrovascular Pathology.

Authors:  Andrea Angeli; Lorenzo di Cesare Mannelli; Elena Trallori; Thomas S Peat; Carla Ghelardini; Fabrizio Carta; Claudiu T Supuran
Journal:  ACS Med Chem Lett       Date:  2018-04-09       Impact factor: 4.345

Review 5.  Mouse models of neurological disorders: a view from the blood-brain barrier.

Authors:  William A Banks
Journal:  Biochim Biophys Acta       Date:  2009-10-29

6.  Adult Changes in Thought study: dementia is an individually varying convergent syndrome with prevalent clinically silent diseases that may be modified by some commonly used therapeutics.

Authors:  Thomas J Montine; Joshua A Sonnen; Kathleen S Montine; Paul K Crane; Eric B Larson
Journal:  Curr Alzheimer Res       Date:  2012-07       Impact factor: 3.498

7.  Regulation of high glucose-induced apoptosis of brain pericytes by mitochondrial CA VA: A specific target for prevention of diabetic cerebrovascular pathology.

Authors:  Tulin O Price; Nader Sheibani; Gul N Shah
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-01-26       Impact factor: 5.187

Review 8.  Prospective of managing impaired brain insulin signalling in late onset Alzheimers disease with excisting diabetic drugs.

Authors:  Gifty M Jojo; Gowthamarajan Kuppusamy; Kousalya Selvaraj; Uday Krishna Baruah
Journal:  J Diabetes Metab Disord       Date:  2019-05-09

9.  Topiramate Protects Pericytes from Glucotoxicity: Role for Mitochondrial CA VA in Cerebromicrovascular Disease in Diabetes.

Authors:  Ping Patrick; Tulin O Price; Ana L Diogo; Nader Sheibani; William A Banks; Gul N Shah
Journal:  J Endocrinol Diabetes       Date:  2015

Review 10.  Brain insulin dysregulation: implication for neurological and neuropsychiatric disorders.

Authors:  Rasoul Ghasemi; Leila Dargahi; Ali Haeri; Maryam Moosavi; Zahurin Mohamed; Abolhassan Ahmadiani
Journal:  Mol Neurobiol       Date:  2013-01-20       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.